kabutan

Kringle Pharma,Inc.(4884) Summary

4884
TSE Growth
Kringle Pharma,Inc.
392
JPY
-4
(-1.01%)
Dec 5, 11:06 am JST
2.52
USD
Dec 4, 9:06 pm EST
Result
PTS
outside of trading hours
391.1
Dec 5, 10:42 am JST
Summary Chart Historical News Financial Result
PER
PBR
2.20
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
392 JPY 2.52 USD
Previous Close Dec 4
396 JPY 2.54 USD
High Dec 5, 9:21 am
394 JPY 2.53 USD
Low Dec 5, 10:49 am
390 JPY 2.51 USD
Volume
7,400
Trading Value
3.00M JPY 0.02M USD
VWAP
392.0 JPY 2.53 USD
Minimum Trading Value
39,200 JPY 252 USD
Market Cap
2.82B JPY 0.02B USD
Number of Trades
19
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
312
1-Year High Jun 12, 2025
3,785
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 948,600
Nov 21, 2025 0 937,200
Nov 14, 2025 0 906,800
Nov 7, 2025 0 921,500
Oct 31, 2025 0 933,800
Company Profile
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein.
Sector
Pharmaceuticals
Kringle Pharma, Inc. is engaged in the research and development of therapeutic drugs for intractable diseases using HGF protein. The company is currently conducting clinical trials for acute spinal cord injury, ALS, vocal cord scarring, and acute kidney injury. For acute spinal cord injury, a Phase III trial is in progress, aiming for a marketing authorization application. For ALS, the company is analyzing the results of a Phase II trial. A Phase III trial is underway for vocal cord scarring, while plans for the next phase of trials for acute kidney injury are being developed. Leveraging the neuroprotective and anti-fibrotic effects of HGF, Kringle Pharma aims to expand its applications to multiple intractable diseases. The company is also strengthening its new pipeline through collaborative research with universities and other companies.